The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
Open Access
Abstract
Despite a great success of immunotherapy in cancer treatment, a great number of patients will become resistant. This review summarizes recent reports on immune checkpoint inhibitor retreatment or rechallenge in order to overcome primary resistance. The systematic review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The search was performed using PubMed, Web of Science and Scopus. In total, 31 articles were included with a total of 812 patients. There were 16 retreatment studies and 13 rechallenge studies. We identified 15 studies in which at least one parameter (overall response rate or disease control rate) improved or was stable at secondary treatment. Interval treatment, primary response to and the cause of cessation for the first immune checkpoint inhibitors seem to be promising predictors of secondary response. However, high heterogeneity of investigated cohorts and lack of reporting guidelines are limiting factors for current in-depth analysis.Keywords
Funding Information
- Foundation For Polish Science (MAB/2018/6, BPN/WAL/2022/1/00024/U/00001)
- NAWA-Polish National Agency for Academic Exchange (MAB/2018/6, BPN/WAL/2022/1/00024/U/00001)
This publication has 66 references indexed in Scilit:
- Ipilimumab After Progression on Anti-Pd-1 Treatment in Advanced MelanomaFuture Oncology, 2016
- Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaNew England Journal of Medicine, 2016
- Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyBritish Journal of Cancer, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Ipilimumab in anti-PD1 refractory metastatic melanomaMelanoma Research, 2016
- PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviewsBMC Health Services Research, 2014
- Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in ItalyBritish Journal of Cancer, 2014
- Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease ControlClinical Cancer Research, 2013
- Combining immunotherapy and targeted therapies in cancer treatmentNature Reviews Cancer, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009